The shifting pattern of cause-specific mortality in a cohort of human immunodeficiency virus-infected and non-infected injecting drug users
Corresponding Author
Inmaculada Ferreros
Unitat d'Epidemiologia i Estadística, Escola Valenciana d'Estudis en Salut (EVES),Valencia, Spain,
CIBER de Epidemiologia y Salud Pública (CIBERESP), Spain,
Dpto Salud Pública, Universidad Miguel Hernández de Alicante, Spain and
Inmaculada Ferreros Villar, Unitat d'Epidemiologia i Estadística.Escola Valenciana d'Estudis en Salut (EVES), C/Juan de Garay 21, 46017 Valencia, Spain. E-mail: [email protected]Search for more papers by this authorBlanca Lumbreras
CIBER de Epidemiologia y Salud Pública (CIBERESP), Spain,
Dpto Salud Pública, Universidad Miguel Hernández de Alicante, Spain and
Search for more papers by this authorIsabel Hurtado
Unitat d'Epidemiologia i Estadística, Escola Valenciana d'Estudis en Salut (EVES),Valencia, Spain,
CIBER de Epidemiologia y Salud Pública (CIBERESP), Spain,
Search for more papers by this authorSantiago Pérez-Hoyos
Unitat d'Epidemiologia i Estadística, Escola Valenciana d'Estudis en Salut (EVES),Valencia, Spain,
CIBER de Epidemiologia y Salud Pública (CIBERESP), Spain,
Dpto Enfermería Comunitaria, Medicina Preventiva y Salud Pública e Historia de la Ciencia, Universidad de Alicante, Spain
Search for more papers by this authorIldefonso Hernández-Aguado
CIBER de Epidemiologia y Salud Pública (CIBERESP), Spain,
Dpto Salud Pública, Universidad Miguel Hernández de Alicante, Spain and
Search for more papers by this authorCorresponding Author
Inmaculada Ferreros
Unitat d'Epidemiologia i Estadística, Escola Valenciana d'Estudis en Salut (EVES),Valencia, Spain,
CIBER de Epidemiologia y Salud Pública (CIBERESP), Spain,
Dpto Salud Pública, Universidad Miguel Hernández de Alicante, Spain and
Inmaculada Ferreros Villar, Unitat d'Epidemiologia i Estadística.Escola Valenciana d'Estudis en Salut (EVES), C/Juan de Garay 21, 46017 Valencia, Spain. E-mail: [email protected]Search for more papers by this authorBlanca Lumbreras
CIBER de Epidemiologia y Salud Pública (CIBERESP), Spain,
Dpto Salud Pública, Universidad Miguel Hernández de Alicante, Spain and
Search for more papers by this authorIsabel Hurtado
Unitat d'Epidemiologia i Estadística, Escola Valenciana d'Estudis en Salut (EVES),Valencia, Spain,
CIBER de Epidemiologia y Salud Pública (CIBERESP), Spain,
Search for more papers by this authorSantiago Pérez-Hoyos
Unitat d'Epidemiologia i Estadística, Escola Valenciana d'Estudis en Salut (EVES),Valencia, Spain,
CIBER de Epidemiologia y Salud Pública (CIBERESP), Spain,
Dpto Enfermería Comunitaria, Medicina Preventiva y Salud Pública e Historia de la Ciencia, Universidad de Alicante, Spain
Search for more papers by this authorIldefonso Hernández-Aguado
CIBER de Epidemiologia y Salud Pública (CIBERESP), Spain,
Dpto Salud Pública, Universidad Miguel Hernández de Alicante, Spain and
Search for more papers by this authorABSTRACT
Aims To monitor changes in cause-specific mortality before and after 1997 according to human immunodeficiency virus (HIV) serological status in a cohort of injecting drug users (IDUs) observed for a 17-year period (1987–2004).
Design Community-based prospective cohort study of IDUs recruited in three acquired immunodeficiency virus (AIDS) prevention centres (1987–96) and followed-up until to 2004.
Methods We obtained annual overall mortality rates and mortality rates by specific causes according to HIV status. Poisson regression models were adjusted to compare mortality rates between calendar periods. Significant changes in slope trends were evaluated by join-point regression. Disease-specific mortality rates were estimated using competing risk models.
Findings From 7186 IDUs recruited (80 677.218 person-years), 1589 deaths were observed with an overall mortality rate of 19.7 per 1000 person-years (95% CI, 18.8–20.7). This rate decreased from 22.9 per 1000 (95% CI, 21.4–24.7) before 1997 to 17.4 per 1000 (95% CI, 16.3–18.6) after 1997 [relative risk (RR) 0.83; 95% confidence interval (CI), 0.75–0.92]. Risk of death for HIV-positive was four times higher than for HIV-negative (RR 4.08; 95% CI, 3.63–4.58). Among HIV-positive individuals a significantly decreased change point in trend was found in 1997 for both total and AIDS mortality. HIV-negative individuals showed a similar pattern for drug overdose, suicide and accident mortality. Both groups showed an increase in proportional mortality by liver-related causes, cardiovascular diseases and cancer. Furthermore, a progressively increasing trend was observed for the three causes. However, there were no significant differences according to serological groups.
Conclusions Cardiovascular and cancer mortality are increasing among IDUs, but the increases are not related to HIV infection. We have not found a link between highly active antiretroviral therapy (HAART) introduction and increases in mortality for specific causes.
References
- 1 Vlahov D., Wang C. L., Galai N., Bareta J., Mehta S. H., Strathdee S. A. et al. Mortality risk among new onset injection drug users. Addiction 2004; 99: 946–54.
- 2 Prins M., Sabin C. A., Lee C. A., Devereux H., Coutinho R. A. Pre-AIDS mortality and its association with HIV disease progression in haemophilic men, injecting drug users and homosexual men. AIDS 2000; 14: 1829–37.
- 3 Hulse G. K., English D. R., Milne E., Holman C. D. The quantification of mortality resulting from the regular use of illicit opiates. Addiction 1999; 94: 221–9.
- 4 Goedert J. J., Pizza G., Gritti F. M., Costigliola P., Boschini A., Bini A. et al. Mortality among drug users in the AIDS era. Int J Epidemiol 1995; 24: 1204–10.
- 5 European Monitoring Centre for Drugs and Drug Addiction (ELE2). Mortality of drug users in the EU: coordination of implementation of new cohort studies, follow-up and analysis of existing cohorts and development of new methods and outputs. Lisbon: EMCDDA; 2002.
- 6 Tyndall M. W., Craib K. J., Currie S., Li K., O'Shaughnessy M. V., Schechter M. T. Impact of HIV infection on mortality in a cohort of injection drug users. J Acquir Immune Defic Syndr 2001; 28: 351–7.
- 7 Detels R., Munoz A., McFarlane G., Kingsley L. A., Margolick J. B., Giorgi J. et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998; 280: 1497–503.
- 8 Mocroft A., Madge S., Johnson A. M., Lazzarin A., Clumeck N., Goebel F. D. et al. A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. J Acquir Immune Defic Syndr 1999; 22: 369–78.
- 9 Egea J. M., Muga R., Sirera G., Clotet B., Tor J., Ardevol M. et al. Initiation, changes in use and effectiveness of highly active anti-retroviral therapy in a cohort of injecting drug users. Epidemiol Infect 2002; 129: 325–33.
- 10 Celentano D. D., Vlahov D., Cohn S., Shadle V. M., Obasanjo O., Moore R. D. Self-reported antiretroviral therapy in injection drug users. JAMA 1998; 280: 544–6.
- 11 Sherer R. Adherence and antiretroviral therapy in injection drug users. JAMA 1998; 280: 567–8.
- 12 Wood E., Hogg R. S., Yip B., Harrigan P. R., O'Shaughnessy M. V., Montaner J. S. The impact of adherence on CD4 cell count responses among HIV-infected patients. J Acquir Immune Defic Syndr 2004; 35: 261–8.
- 13 Perez-Hoyos S., Ferreros I., Del Amo J., Muga R., Del Romero J., De Olalla P. G. et al. Survival and progression to AIDS in a seroconverter cohort in the post-highly active antiretroviral therapy era: effectiveness goes on. AIDS 2006; 20: 289–91.
- 14 Perez-Hoyos S., Del Amo J., Muga R., Del Romero J., Garcia D. O., Guerrero R. et al. Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category. AIDS 2003; 17: 353–9.
- 15 Perez-Hoyos S., Avino M., Hernandez I., Gonzalez J., Ruiz I. Tiempo libre de SIDA y supervivencia de una cohorte de usuarios de drogas por via parenteral seroconvertores frente al VIH [AIDS-free time and survival of an injecting drug users HIV seroconvertors cohort]. Gac Sanit 1999; 13: 337–45.
- 16 Smit C., Geskus R., Walker S., Sabin C., Coutinho R., Porter K. et al. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 2006; 20: 741–9.
- 17 Babiker A., Darbyshire J., Pezzotti P., Porter K., Rezza G., Walker S. A. et al. Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int J Epidemiol 2002; 31: 951–8.
- 18 Valdez H., Chowdhry T. K., Asaad R., Woolley I. J., Davis T., Davidson R. et al. Changing spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995–1999. Clin Infect Dis 2001; 32: 1487–93.
- 19 Mocroft A., Brettle R., Kirk O., Blaxhult A., Parkin J. M., Antunes F. et al. Changes in the cause of death among HIV-positive subjects across Europe: results from the EuroSIDA study. AIDS 2002; 16: 1663–71.
- 20 Sackoff J. E., Hanna D. B., Pfeiffer M. R., Torian L. V. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med 2006; 145: 397–406.
- 21 Bica I., McGovern B., Dhar R., Stone D., McGowan K., Scheib R. et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 492–7.
- 22 Mocroft A., Soriano V., Rockstroh J., Reiss P., Kirk O., De Wit S. et al. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS 2005; 19: 2117–25.
- 23 Kwong G. P., Ghani A. C., Rode R. A., Bartley L. M., Cowling B. J., Da Silva B. et al. Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use. AIDS 2006; 20: 1941–50.
- 24 Krentz H. B., Kliewer G., Gill M. J. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Med 2005; 6: 99–106.
- 25 Crum N. F., Riffenburgh R. H., Wegner S., Agan B. K., Tasker S. A., Spooner K. M. et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 2006; 41: 194–200.
- 26 Avino Rico M. J., Hernandez-Aguado I., Perez H. S., Garcia DlH., Ruiz I., Bolumar M. F. Incidencia de la infeccion por el virus de la inmunodeficiencia humana tipo 1 (VIH-1) en usuarios de drogas por via parenteral [The incidence of human immunodeficiency virus type-1 (HIV-1) infection in parenteral drug users]. Med Clin (Barc) 1994; 102: 369–73.
- 27 Hernandez-Aguado I., Bolumar F. Determinants of HIV-1 infection in intravenous drug users in Valencia, Spain, 1987–1991. Int J Epidemiol 1993; 22: 537–42.
- 28 Hernandez-Aguado I., Ruiz I., Bolumar F., Perez-Hoyos S., Fernandez-Garcia E., Santos C. et al. Sharing of injection equipment among 3755 intravenous drug users in Valencia, Spain, 1987–1992. Int J Epidemiol 1994; 23: 602–7.
- 29 Lumbreras B., Jarrin I., Del Amo J., Perez-Hoyos S., Muga R., Garcia-de la Hera M. et al. Impact of hepatitis C infection on long-term mortality of injecting drug users from 1990 to 2002: differences before and after HAART. AIDS 2006; 20: 111–16.
- 30
Kim H. J.,
Fay M. P.,
Feuer E. J.,
Midthune D. N.
Permutation tests for joinpoint regression with applications to cancer rates.
Stat Med
2000; 19: 335–51.
10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z CAS PubMed Web of Science® Google Scholar
- 31 National Cancer Institute. Jointpoint Regression Program, version 2.7. 2003. Available at: http://srab.cancer.gov/jointpoint (accessed 2003).
- 32 Tai B. C., Machin D., White I., Gebski V. Competing risks analysis of patients with osteosarcoma: a comparison of four different approaches. Stat Med 2001; 20: 661–84.
- 33 Llorca J., Delgado-Rodriguez M. Competing risks in absence of independence: impact of AIDS on liver function failure mortality, and lung cancer on ischemic heart disease mortality. J Clin Epidemiol 2000; 53: 1145–9.
- 34 Putter H., Fiocco M., Geskus R. B. Tutorial in biostatistics: competing risks and multi-state models. Stat Med 2007; 26: 2389–430.
- 35 Voirin N., Trepo C., Miailhes P., Touraine J. L., Chidiac C., Peyramond D. et al. Survival in HIV-infected patients is associated with hepatitis C virus infection and injecting drug use since the use of highly active antiretroviral therapy in the Lyon observational database. J Viral Hepat 2004 2006; 11: 559–62.
- 36 Amin J., Kaye M., Skidmore S., Pillay D., Cooper D. A., Dore G. J. HIV and hepatitis C coinfection within the CAESAR study. HIV Med 2004; 5: 174–9.
- 37 Benhamou Y., Bochet M., Di Martino V., Charlotte F., Azria F., Coutellier A. et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30: 1054–8.
- 38 Louie J. K., Hsu L. C., Osmond D. H., Katz M. H., Schwarcz S. K. Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994–1998. J Infect Dis 2002; 186: 1023–7.
- 39 Prins M., Hernandez A. I., Brettle R. P., Robertson J. R., Broers B., Carre N. et al. Pre-AIDS mortality from natural causes associated with HIV disease progression: evidence from the European Seroconverter Study among injecting drug users. AIDS 1997; 11: 1747–56.
- 40 De La Fuente L., Bravo M. J., Barrio G., Parras F., Suarez M., Rodes A. et al. Lessons from the history of the human immunodeficiency virus/acquired immunodeficiency syndrome epidemic among Spanish drug injectors. Clin Infect Dis 2003; 37: S410–15.
- 41 Garcia B. F., Godoy C., Perez S., Bolumar F. Codificacion multiple de las causas de muerte: de morir ‘por’ a morir ‘con’[Multiple codification of the causes of death: from dying ‘of’ to dying ‘from’]. Gac Sanit 1992; 6: 53–7.
- 42 Hernandez-Aguado I., Santos R. C., Torrella R. A., Avino M. J., Fernandez G. E., Garcia de la Herra M. et al. Prevalence of human immunodeficiency virus infection among parenteral drug users in the community of Valencia 1987–1991. Med Clin (Barc) 1993; 100: 164–7.
